TuHURA Biosciences, Inc. (NASDAQ:HURA) Given Consensus Rating of "Buy" by Analysts

TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) has been assigned a consensus recommendation of "Buy" from the five research firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $12.67.

HURA has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of TuHURA Biosciences from a "sell" rating to a "hold" rating in a research note on Friday. Brookline Capital Management raised shares of TuHURA Biosciences to a "strong-buy" rating in a report on Monday, June 23rd. Finally, HC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of TuHURA Biosciences in a report on Friday, May 16th.

TuHURA Biosciences Stock Up 7.5%

Shares of NASDAQ:HURA traded up $0.19 on Friday, hitting $2.74. 357,940 shares of the company's stock were exchanged, compared to its average volume of 263,580. The business's 50 day simple moving average is $2.81 and its two-hundred day simple moving average is $3.44. TuHURA Biosciences has a 12 month low of $1.80 and a 12 month high of $7.93.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

Hedge Funds Weigh In On TuHURA Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Accent Capital Management LLC acquired a new position in shares of TuHURA Biosciences in the 4th quarter valued at $29,000. TT Capital Management LLC purchased a new position in TuHURA Biosciences during the fourth quarter worth about $41,000. Jefferies Financial Group Inc. acquired a new stake in shares of TuHURA Biosciences during the fourth quarter valued at about $54,000. Bank of America Corp DE purchased a new stake in shares of TuHURA Biosciences in the 4th quarter valued at approximately $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of TuHURA Biosciences in the 4th quarter worth approximately $61,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.